Marc Pondel

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Locally Advanced

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Radiation Therapy

Top Venues

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Ivo Abraham, Matthias Calamia, Nimer S Alkhatib, Marc Pondel, Karen M MacDonald
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics 27 (sup3) (2024)
Karen M MacDonald, Marc Pondel, Ivo Abraham
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer. Journal of medical economics (2024)
Karen M MacDonald, Marc Pondel, Ivo Abraham
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics 27 (sup3) (2024)
Karen M MacDonald, Marc Pondel, Ivo Abraham
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics (2024)
Ivo Abraham, Matthias Calamia, Nimer S Alkhatib, Marc Pondel, Karen M MacDonald
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics (2024)
Karen M MacDonald, Marc Pondel, Ivo Abraham
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer. Journal of medical economics 27 (sup3) (2024)
Karen M MacDonald, Marc Pondel, Ivo Abraham
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics 27 (sup3) (2024)